Beijing Luzhu Biotechnology Co., Ltd.

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.

Industry

Biotechnology

Sector

Healthcare

Headquarters

CN

CEO

Jian Kong

Listed since

May 8, 2023

Employees

193